Life sciences entrepreneur, computational scientist, and patent agent. @ChrisB_biotech@mstdn.social Rom 8:18
Toronto, Ontario
Joined November 2018
- Tweets221
- Following117
- Followers63
- Likes793
Chris Barden retweeted
These are the small companies and research groups @CARB_X supports at global scale. Not one or two, but dozens at a time. They need both money and scientific, business, and technical help turning ideas into products
Do you know who is leading AMR research today?
▶ 93% of clinical R&D is lead by small companies
▶ 86.7% of preclinical R&D too!
Small companies and biotech are at the forefront of antibacterial development.
👉 Read more here who.int/publications/i/item/…
Here is the Treventis #AAIC24 contingent! Drop us a line if you're in Philadelphia this week and would like to meet.
Chris Barden retweeted
Good morning, #AAIC24 attendees! Are you ready to kick off an exciting week of sharing new ideas and discoveries? Scientific sessions start soon. Get today’s schedule at alz.org/aaic.
Chris Barden retweeted
The pharma industry invents medicines that ease suffering & save lives. So why are we so bad at communicating the value being generated? From @PeterKolchinsky rapport.bio/all-stories/erod…
Chris Barden retweeted
What's now for the Amyloid Hypothesis in #Alzheimers?
Several recent studies using monoclonal antibodies show evidence that removing aggregated Aβ from the brains of symptomatic patients can slow the disease progression.
Yes, despite the clinical benefit of these trials still being modest, disease-modifying treatments for Alzheimer's are feasible, and they are going to happen more consistently within the next few years.
I and others are focusing on understanding how soluble amyloid species, not senile plaque or large fibrils, can play a crucial role in synapse loss and neurodegeneration in Alzheimer's.
Oligomeric amyloid, for example (🔵 in the image below), triggers extensive glial activation (🟠astrocytes) in the human brain. By using promising antibodies and optimizing the timing for therapeutic intervention, we might be finally close to helping patients with Alzheimer's and similar neurodegenerative diseases.
A scary photo for an optimistic #FluorescenceFriday
Chris Barden retweeted
To say antimicrobial resistance (AMR) is a problem is an understatement. If nothing changes, by 2050, 10 million AMR-related deaths are expected to occur every year. Explore our resource page to learn about AMR, & how we can combat it. asm.social/1A1 #WAAW #USAAW23
Capping off a successful #BIOEUROPE by uncapping some traditional Bavarian fare! A great conference all around, thanks to all who met up while I was in Munich to speak about @Treventis_corp
Enjoying the capacious and efficient partnering layout this morning at #BIOEUROPE ... Drop me a DM if you'd like to meet and discuss protein #misfolding @Treventis_corp
Chris Barden retweeted
So much can be learned from the Christchurch mutation, not only about potential new treatments but also the pathophysiology of AD broadly. Lots of plaques with few tangles and delayed clinical manifestations. alzforum.org/news/conference…
Chris Barden retweeted
📣 I’m thrilled that 🇨🇦 will be joining Wellcome 🇺🇸🇩🇪🇬🇧and @gatesfoundation providing funds to @CARB_X.
International partnership to coordinate investment in product development is key to saving lives from #AMR.
Government of Canada makes important investment to fight antimicrobial resistance (AMR)
ow.ly/xSSy104GEX1
Pleased to be invited to speak about @Treventis_corp at #MaRSImpactHealth this morning!
I am so proud of our Treventis team's innovation and determination! We look forward to a great partnership with Takeda in Alzheimer's.
Exciting news to share from Treventis! prnewswire.com/news-releases…
Chris Barden retweeted
Exciting news to share from Treventis! prnewswire.com/news-releases…
Chris Barden retweeted
.@aliciadubinski from the @cvandevelde75 reports that stress granule assembly in vivo is deficient in the CNS of mutant TDP-43 ALS mice.
doi.org/10.1093/hmg/ddac206
This is a great step forward for innovative payment models in antimicrobial development. Important that Japan is making this a priority.
Chris Barden retweeted
Drug-resistant infections must be prioritised.
ALT 1 in 5 people who died from drug-resistant infections in 2019 were children under 5. Image shows 5 people, 4 are coloured dark red and 1 is pink. Source: Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis, The Lancet, 2022.
Chris Barden retweeted
Wheelock et al. provide new evidence that low cost and minimally invasive measurements of serum neurofilament light are a useful marker of functional connectivity and cognitive decline in Alzheimer’s disease. bit.ly/3GKBlKb
Chris Barden retweeted
No amount of AD pathology is “normal” per se, but pretty much everyone develops NFTs in their lifetime. Ever wonder what amount of Alzheimer-type pathology is “normal”-ish at any given age? pubmed.ncbi.nlm.nih.gov/3650… #neuropath #alzheimers #neurology
